Staff Reports
The Food and Drug Administration just told REGENXBIO a simple truth: showing a lot of engineered protein in muscle is not the same as proving boys with Duchenne muscular dystrophy actually get better. That regulatory nudge matters for every company chasing gene therapies that raise microdystrophin levels and for the families hoping those therapies will help.
FDA says correlation, not just numbers, will decide RGX-202
REGENXBIO reported strong microdystrophin results from its AFFINITY study. The company says most boys met the lab threshold for protein at Week 12 and average expression looked high. But the FDA pushed back in recent talks: the agency will judge whether microdystrophin can be a surrogate endpoint only if there is convincing evidence the protein level predicts meaningful clinical improvement. Regulators recommended a randomized controlled trial and warned that small, externally controlled analyses will need to be rock-solid to carry the day.
Why that demand is not bureaucratic nitpicking
There is a reason the FDA is asking for real proof. A rival randomized study in this field showed plenty of mini-dystrophin protein but no clear gain in motor scores. And safety problems with an approved microdystrophin product have already made regulators wary. If agencies approve drugs because lab numbers look pretty, we risk exposing children to permanent or irreversible choices — like getting an AAV infusion that makes future dosing impossible — without a real chance they will move or breathe better.
Market pressure versus patient protection
Make no mistake: companies have incentives to chase biomarkers. Hitting a protein threshold is faster and cheaper than running large randomized trials that measure function over time. If regulators accept protein alone as a shortcut, everyone will rush the biomarker finish line and families will be left sorting out who truly benefits. The FDA’s stance forces sponsors to prove clinical benefit, or at least to run a proper randomized trial, instead of selling hope on lab results.
In the end, the sensible position is simple and mercifully old-fashioned: show the kids get better, not just that their muscles glint with lab-made protein. That may slow filings and annoy investors, but it protects patients and preserves the credibility of gene therapy. Let the science earn the approval — because no amount of shiny protein should replace real muscle and real lives getting stronger.
